dr. santin on rationale for trastuzumab in uterine serous carcinoma
Published 6 years ago • 181 plays • Length 1:06Download video MP4
Download video MP3
Similar videos
-
1:24
dr. santin on impact of trastuzumab in uterine serous carcinoma
-
2:03
efficacy results for trastuzumab in her2-positive uterine serous carcinoma
-
2:07
dr. fader on adding trastuzumab to chemo in her2 uterine serous carcinoma
-
1:27
dr. fader on trastuzumab/chemo in her2 uterine serous carcinoma
-
1:45
dr. yadav on the olaparib/neratinib combo in her2 uterine serous carcinoma
-
7:26
standard frontline therapy for endometrial cancer
-
1:22
dr. kauff on challenges in treating uterine cancer
-
5:46
adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for her2-positive breast cancer
-
3:20
dr. hurvitz on eliminating anthracyclines in her2 breast cancer treatment
-
2:10
dr. dizon on pten mutations in endometrial cancer
-
1:27
dr. wingo on the evolution of surgery in endometrial cancer
-
2:17
radiation therapy based on lumina trial | cynthia ma, md, phd | asco22 breast cancer updates
-
6:17
sara tolaney, sabcs 2022: adjuvant paclitaxel and trastuzumab for node-negative her2 breast cancer
-
2:40
redefining the outcome of breast cancer surgery
-
0:59
sequencing her2-targeted therapies in breast cancer
-
2:09
the evolution of her2 targeting in metastatic breast breast cancer
-
1:02
ctdna testing for mrd – reliable, sensitive, and specific, but challenges remain: 2022 esmo florida
-
2:44
sequencing agents for her2 metastatic breast cancer
-
4:05
camizestrant may be superior to fulvestrant in patients with hr-positive, her2-negative bc